文献速递基础与转化研究临床试验与 GCP

既往治疗失败后淋巴瘤的增强型CAR-T细胞治疗

Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.
PubMed 文献 · N Engl J Med · 2025-01-01

本研究评估了分泌白细胞介素-18的抗CD19增强型CAR-T产品huCART19-IL18在既往抗CD19 CAR-T治疗失败的复发或难治性淋巴瘤患者中的安全性、可行性和初步疗效。21例患者接受治疗,细胞因子释放综合征发生率为62%(47%为1或2级),免疫效应细胞相关神经毒性综合征发生率为14%(均为1或2级)。输注后3个月,81%的患者达到完全或部分缓解(90%CI 62-93),52%达到完全缓解(90%CI 33-71)。

要点

  • huCART19-IL18在既往抗CD19 CAR-T治疗失败的淋巴瘤患者中安全性与其他CAR-T治疗一致。
  • 21例患者中细胞因子释放综合征发生率为62%,其中47%为1或2级。
  • 输注后3个月完全或部分缓解率为81%,完全缓解率为52%。

核心结论

  • 在这项小型研究中,huCART19-IL18的安全性特征与其他CAR-T细胞治疗一致,并在低细胞剂量下对既往抗CD19 CAR-T治疗失败的淋巴瘤患者显示出有前景的疗效。

研究设计与样本

  • 研究评估了huCART19-IL18在既往抗CD19 CAR-T细胞治疗后的复发或难治性淋巴瘤患者中的安全性、可行性和初步疗效。
  • 采用3天制备工艺,给予huCART19-IL18阳性细胞,剂量范围为3×10^6至3×10^8。
  • 共21例患者接受了huCART19-IL18治疗。

主要发现

  • 细胞因子释放综合征发生于62%的患者(47%为1或2级),免疫效应细胞相关神经毒性综合征发生于14%(均为1或2级)。
  • 未观察到意外不良事件,所有剂量水平均检测到强劲的CAR-T细胞扩增。
  • 输注后3个月,81%的患者达到完全或部分缓解(90%CI 62-93),52%达到完全缓解(90%CI 33-71)。
  • 中位随访17.5个月(范围3-34个月),中位缓解持续时间为9.6个月(90%CI 5.5-未达到)。

局限性

  • 原文称本研究为小型研究(small study)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armored) CAR T-cell product (huCART19-IL18) that secretes interleukin-18 to enhance antitumor activity. METHODS: In this study, we assessed the safety, feasibility, and preliminary efficacy of huCART19-IL18 in patients with relapsed or refractory lymphoma after previous anti-CD19 CAR T-cell therapy. Using a 3-day manufacturing process, we administered huCART19-IL18-positive cells in doses ranging from 3×106 to 3×108. RESULTS: A total of 21 patients received huCART19-IL18. Cytokine release syndrome occurred in 62% of the patients (47% with grade 1 or 2), and immune effector-cell-associated neurotoxicity syndrome occurred in 14% (all grade 1 or 2). No unexpected adverse events were observed. Robust CAR T-cell expansion was detected across all dose levels. At 3 months after infusion, a complete or partial response was seen in 81% of the patients (90% confidence interval [CI], 62 to 93) and a complete response in 52% (90% CI, 33 to 71). With a median follow-up of 17.5 months (range, 3 to 34), the median duration of response was 9.6 months (90% CI, 5.5 to not reached). CONCLUSIONS: In this small study, huCART19-IL18 had a safety profile consistent with other CAR T-cell treatments and showed promising efficacy at low cell doses in patients with lymphoma after the failure of previous anti-CD19 CAR T-cell therapy. (ClinicalTrials.gov number, NCT04684563.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Svoboda J, Landsburg DJ, Gerson J, et al. Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. N Engl J Med. 2025. PMID: 40334157. doi:10.1056/NEJMoa2408771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。